Table 1.
Patient demographics and clinical characteristics
| Parameters | Placebo, N = 28 | Semaglutide 1 mg, N = 44 | Tirzepatide 15 mg, N = 45 |
|---|---|---|---|
| Age, years | 60.4 ± 7.6 | 63.7 ± 5.9 | 61.1 ± 7.1 |
| Sex, male, n (%) | 21 (75.0) | 34 (77.3) | 31 (68.9) |
| Race, n (%) | |||
| Black or African American | 0 | 0 | 1 (2.2) |
| White | 28 (100.0) | 44 (100.0) | 44 (97.8) |
| Ethnicity, n (%) | |||
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 28 (100.0) | 44 (100.0) | 45 (100.0) |
| HbA1c concentration | |||
| % | 7.9 ± 0.5 | 7.7 ± 0.6 | 7.8 ± 0.7 |
| mmol/mol | 62.9 ± 5.5 | 60.7 ± 6.6 | 62.1 ± 7.9 |
| Fasting glucose, mg/dL | 126.6 ± 23.6 | 128.6 ± 25.0 | 139.3 ± 30.2 |
| Diabetes duration, years | 11.0 ± 6.8 | 12.7 ± 6.1 | 10.2 ± 5.8 |
| Waist circumference, cma | 109.2 ± 12.0 | 109.7 ± 9.2 | 113.5 ± 8.9 |
| BMI, kg/m2 | 32.2 ± 4.0 | 30.8 ± 3.8 | 31.3 ± 5.0 |
| Weight, kg | 98.7 ± 14.6 | 92.7 ± 14.0 | 94.2 ± 14.0 |
| Fat mass, kga | 38.6 ± 10.7 | 35.3 ± 8.0 | 36.8 ± 11.5 |
| Fat-free mass, kga | 59.1 ± 10.3 | 56.3 ± 10.3 | 57.7 ± 9.3 |
| Energy intake, kcala,b | 1,252.7 ± 483.2 | 1,131.0 ± 375.6 | 1,105.0 ± 343.7 |
Data are mean ± SD for the safety population, unless otherwise indicated. n, number of patients in the specified category; N, all randomly assigned patients who took at least one dose of study drug.
a
Total N = 112 (tirzepatide 15 mg, n = 43; semaglutide 1 mg, n = 43; placebo, n = 26) for waist circumference and energy intake; total N = 108 (tirzepatide 15 mg, n = 41; semaglutide, n = 43; placebo, n = 24) for fat mass and fat-free mass from the pharmacodynamic analysis set.
b
Energy intake during ad libitum buffet-style lunch.